| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_27155ed29f9b0bfa281f4b21b26d709a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bcbceb5e1c33512cbf9ad3ad7f0985d0 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-24 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate |
1996-10-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2f744b58c72202dfacebef1475bbfd76 |
| publicationDate |
1997-04-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-9714428-A1 |
| titleOfInvention |
Use of human chorionic gonadotropin in the treatment of kaposi's sarcoma |
| abstract |
The use of hCG Beta-core or hCG fragments, deglycosylated hCG in the treatment of Kaposi's sarcoma is described. Inhibition of tumour production or regression on a variety of KS cell lines is shown. Purified hCG preparations do not inhibit the growth of KS cell lines. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9906438-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0921819-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0939589-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-732972-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6699656-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6319504-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6444639-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0921819-A4
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0939589-A4
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9906438-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9805353-A1 |
| priorityDate |
1995-10-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |